SCHEMBL17815519

SCHEMBL17815519

C=CCC[C@@H]1CCC(=O)C1

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.34
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17815521 1.00 FAAH (0.34) FAAHNOS3NOS1NOS2
SCHEMBL31474861 0.89 FAAH (0.33) FAAHNOS3NOS1NOS2
SCHEMBL20753980 0.88 FAAH (0.36) FAAH
SCHEMBL6515471 0.87 SGPL1 (0.36) FAAH
SCHEMBL28819488 0.80 CYP1A2 (0.30)
SCHEMBL17815526 0.79
SCHEMBL5069027 0.79
SCHEMBL17815530 0.79
SCHEMBL6589588 0.79
SCHEMBL23352117 0.76 CYP1A2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107001273-B Pyridine derivatives 安斯泰来制药株式会社 2020-05-12 CN disclosed
EP-3228616-B1 PYRIDINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2019-10-16 EP disclosed
US-10005762-B2 Pyridine derivatives ASTELLAS PHARMA INC. (JP) 2018-06-26 US disclosed
US-10005762-B2 Pyridine derivatives ASTELLAS PHARMA INC. (JP) 2018-06-26 US disclosed
US-10005762-B2 Pyridine derivatives ASTELLAS PHARMA INC. (JP) 2018-06-26 US disclosed
US-20170362209-A1 PYRIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2017-12-21 US disclosed
US-20170362209-A1 PYRIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2017-12-21 US disclosed
US-20170362209-A1 PYRIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2017-12-21 US disclosed
EP-3228616-A1 PYRIDINE DERIVATIVES Astellas Pharma Inc. (JP) 2017-10-11 EP disclosed
EP-3228616-A1 PYRIDINE DERIVATIVES Astellas Pharma Inc. (JP) 2017-10-11 EP disclosed
WO-2016088864-A1 PYRIDINE DERIVATIVE アステラス製薬株式会社 2016-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005762-B2 Pyridine derivatives LAP3, PREP, DNPEP FAAH 401/4885NOS3 1244/4885NOS1 1565/4885
US-20170362209-A1 PYRIDINE DERIVATIVES LAP3, PREP, DNPEP FAAH 401/4885NOS3 1244/4885NOS1 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.